Spectrum Pharma vs Nabriva Therapeutics Head-To-Head Comparison. I enjoy looking at these comparisons, it confirms for me that there is better value in Spectrum Pharma then in many comparable biotechs. You may recall, back in post 1661, Capital Market Labs did an analysis of SPPi vs MacroGenics. In that analysis Spectrum Pharma Inc defeats MacroGenics: 73 to 27. In this analysis against Nabriva
Spectrum Pharmaceuticals beats Nabriva Therapeutics AG on 8 of the 12 factors compared between the two stocks.
And not only does Spectrum beat Nabriva in 8 out of 12 categories, I think the cancer market where Spectrum competes has more potential than in the antibiotic market where Nabriva competes. Here's the comparison:
Spectrum Pharmaceuticals versus Nabriva Therapeutics AG (NBRV) Head-To-Head Comparison Posted by David Glaser on Jul 20th, 2017 Nabriva Therapeutics AG (NASDAQ: NBRV) and Spectrum Pharmaceuticals (NASDAQ:SPPI) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, valuation, profitabiliy, analyst recommendations, institutional ownership, risk and dividends.
This is a summary of current recommendations for Nabriva Therapeutics AG and Spectrum Pharmaceuticals, as provided by MarketBeat.com.
Nabriva Therapeutics AG currently has a consensus price target of $16.00, indicating a potential upside of 52.53%. Spectrum Pharmaceuticals has a consensus price target of $10.00, indicating a potential upside of 24.38%. Given Nabriva Therapeutics AG’s higher possible upside, research analysts clearly believe Nabriva Therapeutics AG is more favorable than Spectrum Pharmaceuticals. Profitability
This table compares Nabriva Therapeutics AG and Spectrum Pharmaceuticals’ net margins, return on equity and return on assets.
Net Margins Return on Equity Return on Assets Nabriva Therapeutics AG N/A -76.53% -63.87% Spectrum Pharmaceuticals -62.39% -24.06% -13.22%
Risk and Volatility Nabriva Therapeutics AG has a beta of 1.65, indicating that its share price is 65% more volatile than the S&P 500. Comparatively, Spectrum Pharmaceuticals has a beta of 1.49, indicating that its share price is 49% more volatile than the S&P 500.
Institutional & Insider Ownership 56.7% of Nabriva Therapeutics AG shares are held by institutional investors. Comparatively, 67.3% of Spectrum Pharmaceuticals shares are held by institutional investors. 14.5% of Spectrum Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Valuation and Earnings This table compares Nabriva Therapeutics AG and Spectrum Pharmaceuticals’ gross revenue, earnings per share (EPS) and valuation.
Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio Nabriva Therapeutics AG $6.74 million 4.23 -$55.28 million ($2.47) -4.25 Spectrum Pharmaceuticals $131.68 million 4.79 -$49.21 million ($1.08) -7.44
Spectrum Pharmaceuticals has higher revenue and earnings than Nabriva Therapeutics AG. Spectrum Pharmaceuticals is trading at a lower price-to-earnings ratio than Nabriva Therapeutics AG, indicating that it is currently the more affordable of the two stocks.
Summary Spectrum Pharmaceuticals beats Nabriva Therapeutics AG on 8 of the 12 factors compared between the two stocks.
Nabriva Therapeutics AG Company Profile Nabriva Therapeutics AG is an Austria-based clinical-stage biopharmaceutical company engaged in the research and development of antibiotics to treat infections. Its lead product candidate, lefamulin, is a pleuromutilin antibiotic for systemic administration in humans. The Company develops both intravenous (IV) and oral formulations of lefamulin for the treatment of community-acquired bacterial pneumonia (CABP). The Company also develops BC-7013, a semi-synthetic compound derived from pleuromutilin for the topical treatment of Gram-positive infections, including uncomplicated skin and skin structure infections (uSSIs). It is a spin-off from Sandoz GmbH Antibiotics Research Institute (ABRI) in Vienna, Austria.
Spectrum Pharmaceuticals Company Profile Spectrum Pharmaceuticals, Inc. is a biotechnology company. The Company operates through developing and commercializing oncology and hematology drug products segment. It has a product portfolio consisting of both commercial stage and development stage products that address various cancer types. The Company has six approved oncology/hematology products that target different types of cancer, including non-Hodgkin’s lymphoma (NHL), advanced metastatic colorectal cancer (mCRC), acute lymphoblastic leukemia (ALL) and multiple myeloma (MM). It also has three drugs in mid-to-late stage development, which include ROLONTIS for chemotherapy-induced neutropenia; QAPZOLA for immediate intravesical instillation in post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer (NMIBC), and POZIOTINIB, a pan-human epidermal growth factor receptor (HER) inhibitor used in the treatment of patients with a range of solid tumors, including breast and lung cancer.
